Cancer Biomarkers Market Size, Share, and Trends 2026 to 2035

Revenue, 2025

USD 15.58 Bn

Forecast Year, 2035

USD 47.14 Bn

CAGR, 2026 - 2035

11.71%

Report Coverage

Global

What is the Cancer Biomarkers Market Size?

The global cancer biomarkers market size was calculated at USD 15.58 billion in 2025 and is predicted to increase from USD 17.49 billion in 2026 to approximately USD 47.14 billion by 2035, expanding at a CAGR of 11.71% from 2026 to 2035

Cancer Biomarkers Market Key Takeaways

• North America led the global market with the highest market share of 36% in 2025.
• By type, the breast cancer segment held the largest market share in 2025.
• By application, the diagnostics segment captured the biggest revenue share in 2025.
• By biomolecule, the genetic biomarkers segment registered the maximum market share in 2025.

Cancer Biomarkers Market Growth Factors

The cancer biomarkers are used in the diagnosis and treatment of cancer. One of the prominent factors driving the growth of the global cancer biomarkers market is rising incidences of cancer all around the world. According to the World Health Organization (WHO), cancer is the biggest cause of death worldwide, with approximately 10 million fatalities expected in 2020, for almost one in every six deaths. The most frequent cancers are lung cancer, breast cancer, rectum cancer, and prostate cancer. Due to all these cancers, the development of cancer biomarkers has become necessity in the market.

Another factor driving the growth of the global cancer biomarkers market is rising geriatric population. The old people are more prone to life threatening disorders such as cancer. Thus, these people require utmost care and quick treatment against such diseases. In addition, the technological advancements are also creating growth prospects for the expansion of the global cancer biomarkers market. Thus, the adoption of innovative technologies is helping to develop novel cancer biomarkers in the global market.

Furthermore, the government from developing and developed nations is highly investing in the research and development projects for the development of cancer biomarkers. Moreover, market players from private and public sectors are collaborating with each other for the development of cancer biomarkers. All of these aforementioned factors are creating lucrative opportunities for the growth and development of the global cancer biomarkers market over the projected period.

Market Outlook

• Start-up Ecosystem: The start-up growth is measurably high due to its tech offerings for the discovery, the multi-omics unification, and innovations in the liquid biopsy. North America is leading the cancer biomarker start-ups. The robust and promising technologies are making space for smart minds to flourish in the cancer biomarker sector and contribute more intelligence to the traditional healthcare system.
• Industry growth overview:The industry growth is fuelled by the major transition into precision oncology. Alongside, the rising cancer cases are bringing new approaches, clinical innovations, and partnerships in the queue. The rising demand for multi-omics platforms and Next-Generation Sequencing (NGS) has changed the whole dynamic of the public and private hospitals for good.
  
  The convenient, delicate care for this extreme cancer condition has introduced new tech and science-driven innovations and accelerated growth in cancer biomarkers.

Market Scope

On the other hand, the factors such as uncontrolled government laws and reimbursement regulations and expensive drug development are hindering the growth of the global cancer biomarkers market. However, the market for cancer biomarkers is expected to grow due to growing advancements in the field of cancer treatment. In addition, expansion of healthcare sector is driving the growth of the global cancer biomarkers market during the forecast period.

The key market players are adopting various strategies for the growth of the global cancer biomarkers market. The market players are also collaborating with the government agencies for the development of new products in the cancer biomarkers market.

Segment Insights

Type Insights

The breast cancer segment dominated the cancer biomarkers market in 2025. According to the World Health Organization (WHO), breast cancer affected 2.3 million women globally in 2020, with 685,000 fatalities. Breast cancer has been diagnosed in 7.8 million women in the previous five years as of the end of 2020, making it the most common cancer in the world. Thus, the growing prevalence of breast cancer is driving the growth of the segment.

The lung cancer segment is fastest growing segment of the cancer biomarkers market in 2025. Lung cancer is a disease that primarily affects the elderly population. The majority of those diagnosed with lung cancer are 65 or older; only a small percentage of those diagnosed are under 45. When persons are diagnosed, they are typically around 70 years old. Thus, growing geriatric population is boosting the segment growth.

Application Insights

The diagnostics segment dominated the cancer biomarkers market in 2025. The factors such as growing development of cancer biomarkers based on oncology tests with high efficiency and effectiveness and growing government initiatives are driving the growth of the segment during the forecast period.

The personalized medicine segment is fastest growing segment during the forecast period. The segment is growing due to the growing awareness among healthcare practitioners about cancer biomarkers. In addition, the demand for personalized medicines is also growing. One of the key factors driving the segment growth is approvals on diagnostic tests are quite easy nowadays which is creating demand for cancer biomarkers.

Biomolecule Insights

The genetic biomarkers segment dominated the cancer biomarkers market in 2025. The genetic biomarkers are used on a large scale and are very efficient and effective in nature. The genetic biomarkers are extensively used for the treatment and diagnosis of cancer. Thus, all of these factors are boosting the segment growth.

The epigenetics segment is fastest growing segment over the forecast period. One of the key drivers boosting the growth of the segment is growing research for development of novel biomarkers. In addition, market players are collaborating with pharmaceutical firms, which are contributing towards the segment growth.

Regional Insights

U.S. Cancer Biomarkers Market Size and Growth 2026 to 2035

The U.S. cancer biomarkers market size was estimated at USD 3.88 billion in 2025 and is predicted to be worth around USD 12.24 billion by 2035, at a CAGR of 12.17% from 2026 to 2035.

North America dominated the cancer biomarkers market in 2025. The U.S. dominated the cancer biomarkers market in North America region. The North America region has a large number of market players operating in cancer biomarkers market. The U.S. government is heavily investing in research and development activities for the development of novel products. In addition, adoption of innovative and advanced technologies is driving the growth of the cancer biomarkers market in North America region.

Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period. The cancer biomarkers market in Asia-Pacific region is being driven by growing prevalence of cancer. In addition, the government is constantly funding development activities for developing new products. Thus, rising awareness of cancer biomarkers is also boosting the growth of the market in Asia-Pacific region.

Europe's Advancements' Impact on Cancer Biomarkers

Europe's valuable advancements are bringing a transition to a one-for-all idea in the biomarker-driven precision drugs. Europe's Beating Cancer Plan made space for most of the effective technological advancements to bring equal access and early diagnosis to the biomarker testing space throughout the EU.

Alongside, the European Health Data Space (EHDS) framework helped researchers to choose its advanced idea at the right place without disturbing the drug discovery part. The impact on the clinical outcomes also mitigated toxicity.

Latin America's Initiatives in the Cancer Biomarkers Sector

Latin America's major initiatives include the Consortium for Lung Cancer Research, Latin American Cooperative Oncology Group (LACOG), and US-Latin America Cancer Research Network (US-LACRN). The regional initiatives mainly aims on tightening the regional research via cooperative firms, identifying the genetic changes (study) of the general public, and evaluating molecular diagnostics.
The industry, public, and private collaborations are a boon to the regional initiatives. Brazil's Lighthouse Projects are on track to leverage clinical trials and biomarker development.

Value Chain Analysis of the Cancer Biomarkers Market

R&D: R&D in cancer biomarkers is highly influenced by the multi-omics data, robust liquid biopsy technologies, and AI integration. The discovery of more markers in the biological evaluation is empowering precision oncology.

• Key Players – QIAGEN, F. Hoffmann-La Roche Ltd, and Abbott Laboratories.

Formulation and Final Dosage Preparation:The formulation and final dosage preparation of the cancer biomarker is basically monitored to the biomarker-determined precision. The advanced drug formulations are in heavy demand in the cancer biomarker sector.

• Key Players – Cipla Ltd., Getwell Pharma, and Pinnacle Life Science (India).

Distribution to Hospitals, Pharmacies:The distribution has many layers, like specialty distributors, diagnostic laboratories, and pharmaceutical manufacturers. As a part of the upgradation to the distribution channel, the Direct-to-Pharmacy models are developing direct interaction with the network speciality pharmacies bonded with purchase contracts.

• Key Players – Thermo Fisher Scientific, Inc. (US), Guardant Health, Inc. (US), and Agilent Technologies, Inc. (US).

Cancer Biomarkers Market Companies

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Abbott Laboratories
• Exact Sciences
• Meso Scale Diagnostics LLC
• Seegene Technologies Inc.
• Siemens Healthineers

Segments Covered in the Report

By Type

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Liver Cancer
• Lung Cancer
• Others

By Biomolecule

• Genetic Biomarkers
• Epigenetic Biomarkers
• Metabolic Biomarkers
• Proteomic Biomarkers
• Others

By Application

• Drug Discovery and Development
• Diagnostics
• Personalized Medicine
• Others

By Profiling Technology

• Omic Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics-based Tests

By End User

• Hospitals
• Academic and Cancer Research Institutes
• Ambulatory Surgical Centres
• Diagnostic Laboratories

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa